Executive readout · one minute
Call research workspace
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
ONC
$347.48
-2.40%
ONC · BeOne Medicines Ltd.
$347.48
-8.53 (-2.40%)
At close · Aug 14
Market Cap
$513.62B
Shares
1.48B
All earnings calls
Earnings call · FY2026 Q1
BeOne Medicines Ltd. Q1 FY2026 Earnings Call
BeOne Medicines Ltd. Q1 FY2026 Earnings Call
Forward guidance
4 guided metrics
Management's latest ranges and targets are included below.
Research coverage
3 live sources
Switch sources without leaving this page or losing your listening position.
Revenue
$1.51B
+35.5% YoY
Diluted EPS
$0.15
Gross margin
89.0%
+3.8 pp YoY
Net income
$227.36M
+17802.1% YoY
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed May 6, 2026.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Total revenue
Full Year 2026
|
$6.3B – $6.5B | — | |
|
GAAP operating expenses (combined R&D and SG&A)
Full Year 2026
|
$4.7B – $4.9B | GAAP | |
|
GAAP operating income
table
Full Year 2026
|
$750M – $850M | GAAP | |
|
Non-GAAP operating income
table
Full Year 2026
|
$1.45B – $1.55B | Non-GAAP |
Quarter detail
How the reported period landed and where the business moved.
Company presentation
Slides
13 pages · use arrow keys or swipe to navigate
SEC filing · Item 2.02
8-K earnings release
Filed May 6, 2026 · complete as-filed document
SEC periodic report
10-Q report
Filed May 6, 2026 · complete as-filed document